-+ 0.00%
-+ 0.00%
-+ 0.00%

Autonomix Medical Reiterates Plans For Follow-on Phase To PoC 2 Evaluating Safety And Effectiveness Of Delivering Transvascular Energy To Ablate Relevant Problematic Nerves And Mitigate Cancer Pain

Benzinga·05/13/2025 13:25:52
Listen to the news

Follow-on expansion phase expected to begin in Q2 2025

THE WOODLANDS, TX, May 13, 2025 (GLOBE NEWSWIRE) -- – Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today reiterated its plans for a follow-on phase to its proof-of-concept human clinical trial ("PoC 2") evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate cancer pain. Additionally, the Company announced the release of a Virtual Investor CEO Connect segment discussing the PoC 2 phase. Access the segment here.

As previously announced, based on the positive results demonstrated in the initial phase of the Company's first-in-human proof-of-concept trial ("PoC 1") in patients with severe pancreatic cancer pain, Autonomix will initiate the follow-on PoC 2 phase in a market expansion opportunity which has the potential to double the addressable market beyond pancreatic cancer pain by evaluating additional visceral cancers that signal pain through the Celiac Plexus and earlier stage pancreatic cancers with moderate to severe pain. The Company's PoC 2 phase is on track to commence in the second quarter of 2025.